Find Doxylamine manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Canada

Canada

0

Australia

Australia

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 469-21-6, Dossilamina, Doxylaminum, Doxilminio, (+/-)-doxylamine, 2-dimethylaminoethoxyphenylmethyl-2-picoline
Molecular Formula
C17H22N2O
Molecular Weight
270.37  g/mol
InChI Key
HCFDWZZGGLSKEP-UHFFFAOYSA-N
FDA UNII
95QB77JKPL

Doxylamine
Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.
Doxylamine is an Antihistamine. The mechanism of action of doxylamine is as a Histamine Receptor Antagonist.
1 2D Structure

Doxylamine

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N,N-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine
2.1.2 InChI
InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3
2.1.3 InChI Key
HCFDWZZGGLSKEP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C
2.2 Other Identifiers
2.2.1 UNII
95QB77JKPL
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 469-21-6

2. Dossilamina

3. Doxylaminum

4. Doxilminio

5. (+/-)-doxylamine

6. 2-dimethylaminoethoxyphenylmethyl-2-picoline

7. N,n-dimethyl-2-(1-phenyl-1-pyridin-2-ylethoxy)ethanamine

8. N,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine

9. Nci C60684

10. Doxylamine (inn)

11. Phenyl-2-pyridylmethyl-beta-n,n-dimethylaminoethyl Ether

12. 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine

13. Ethanamine, N,n-dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)-

14. Ethanamine, N,n-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]-

15. 95qb77jkpl

16. Chebi:51380

17. Dossilamina [dcit]

18. Alsadorm

19. Mereprine

20. Doxylaminum [inn-latin]

21. Doxilminio [inn-spanish]

22. Decapryn (tn)

23. Doxylamine [inn]

24. Doxylamine [inn:ban]

25. Doxilamina

26. Dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine

27. N,n-dimethyl-2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethanamine

28. N,n-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethan-1-amine

29. Pyridine, 2-[.alpha.-[2-(dimethylamino)ethoxy]-.alpha.-methylbenzyl]-

30. Hsdb 5184

31. Einecs 207-414-2

32. Unii-95qb77jkpl

33. Brn 0230379

34. N,n-dimethyl-2-(1-phenyl-1-(pyridin-2-yl)ethoxy)ethanamine

35. R-doxylamine

36. Pyridine, 2-(.alpha.-(2-(dimethylamino)ethoxy)-.alpha.-methylbenzyl)-

37. Spectrum_001014

38. Doxylamine [mi]

39. Prestwick0_000027

40. Prestwick1_000027

41. Prestwick2_000027

42. Prestwick3_000027

43. Pyridine, 2-(alpha-(2-(dimethylamino)ethoxy)-alpha-methylbenzyl)-

44. Spectrum2_000115

45. Spectrum3_000409

46. Spectrum4_000528

47. Spectrum5_000949

48. Doxylamine [hsdb]

49. Doxylamine [vandf]

50. Ec 207-414-2

51. Schembl4709

52. Chembl1004

53. Doxylamine [who-dd]

54. Lopac0_000348

55. Bspbio_000093

56. Bspbio_001938

57. Kbiogr_001135

58. Kbioss_001494

59. 5-21-03-00508 (beilstein Handbook Reference)

60. Divk1c_000841

61. Spbio_000130

62. Spbio_002014

63. Bpbio1_000103

64. Gtpl7171

65. Dtxsid1022970

66. Kbio1_000841

67. Kbio2_001494

68. Kbio2_004062

69. Kbio2_006630

70. Kbio3_001158

71. Ninds_000841

72. Hms3604l05

73. Bcp09058

74. N,n-dimethyl-2-[(1-phenyl-1-pyridin-2-ylethyl)oxy]ethanamine

75. Stl018676

76. Akos005657227

77. Ccg-204443

78. Db00366

79. Sdccgsbi-0050336.p005

80. Idi1_000841

81. Ncgc00021147-02

82. Ncgc00021147-03

83. Ncgc00021147-04

84. Ncgc00021147-05

85. Ncgc00021147-06

86. Ncgc00021147-08

87. Ncgc00021147-09

88. Ncgc00021147-13

89. Ncgc00021147-21

90. Ncgc00089789-02

91. Ncgc00089789-04

92. Ncgc00089789-05

93. Ac-15949

94. Sbi-0050336.p004

95. Db-051407

96. Ab00053466

97. Ft-0603401

98. D07878

99. Ab00053466-18

100. Ab00053466_19

101. Ab00053466_20

102. .alpha.-dimethylaminoethoxyphenylmethyl-2-picoline

103. 469d216

104. L001076

105. Q423390

106. Brd-a44008656-036-05-0

107. Brd-a44008656-036-15-9

108. Phenyl-2-pyridylmethyl-.beta.-n,n-dimethylaminoethyl Ether

109. N,n-dimethyl-2-[1-phenyl-1-(2-pyridinyl)ethoxy]ethanamine #

110. 2-(.alpha.-(2-(dimethylamino)ethoxy)-.alpha.-methylbenzyl)pyridine

111. 2-(.alpha.(2-(dimethylamino)ethoxy)-.alpha.-methylbenzyl)pyridine

2.4 Create Date
2005-03-25
3 Chemical and Physical Properties
Molecular Weight 270.37 g/mol
Molecular Formula C17H22N2O
XLogP32.5
Hydrogen Bond Donor Count0
Hydrogen Bond Acceptor Count3
Rotatable Bond Count6
Exact Mass270.173213330 g/mol
Monoisotopic Mass270.173213330 g/mol
Topological Polar Surface Area25.4 Ų
Heavy Atom Count20
Formal Charge0
Complexity276
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Therapeutic Uses

Anti-Allergic Agents; Antiemetics; Antitussive Agents; Histamine H1 Antagonists; Sedatives, Nonbarbiturate

National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)


ANTIHISTAMINIC AGENT PROBABLY EFFECTIVE FOR SYMPTOMATIC TREATMENT OF... ALLERGIC RHINITIS, VASOMOTOR RHINITIS, ALLERGIC CONJUNCTIVITIS DUE TO INHALANT ALLERGENS & FOODS, MILD, UNCOMPLICATED ALLERGIC SKIN MANIFESTATIONS OF URTICARIA & ANGIOEDEMA, AMELIORATION & PREVENTION OF...REACTIONS TO BLOOD OR PLASMA... /SUCCINATE/

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1061


VET USE: AS ARE OTHER ANTIHISTAMINES IN STOMATITIS, LAMINITIS, URTICARIA, RESPIRATORY DISORDERS, BLOAT, & INDIGESTION IN CATTLE; IN URTICARIA & LAMINITIS IN HORSES; IN DERMATITIS, URTICARIA, MOTION SICKNESS, & IN PREVENTION OF DEPIGMENTATION IN BLUE NOSED DOGS. /SUCCINATE/

Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 190


Antihistamines are indicated in the prophylactic and symptomatic treatment of perennial and seasonal allergic rhinitis, vasomotor rhinitis, and allergic conjunctivitis due to inhalant allergens and foods. /Antihistamines; Included in US product labeling/

USP Convention. USPDI - Drug Information for the Health Care Professional. 16th ed. Volume I. Rockville, MD: U.S. Pharmaceutical Convention, Inc. 1996 (Plus updates)., p. 324


For more Therapeutic Uses (Complete) data for DOXYLAMINE (9 total), please visit the HSDB record page.


4.2 Drug Warning

PERSONS TAKING ANTIHISTAMINES SHOULD BE ALERTED TO THEIR SEDATIVE EFFECTS & SHOULD BE CAUTIONED NOT TO DRIVE AUTOMOBILE, FLY AIRPLANE, OR OPERATE HAZARDOUS MACHINERY... /ANTIHISTAMINES/

Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 1057


VET: USE OF ANTIHISTAMINES IN STOMATITIS, GANGRENOUS MASTITIS, METRITIS, & TOXIC ENGORGEMENTS HAVE BEEN QUESTIONED. /SUCCINATE/

Rossoff, I.S. Handbook of Veterinary Drugs. New York: Springer Publishing Company, 1974., p. 190


Like other antihistamines, doxylamine should not be used in premature or full-term neonates. Safety and efficacy of doxylamine as a nighttime sleep aid in children younger than 12 years of age have not been established. In addition, children may be more prone than adults to paradoxically experience CNS stimulation rather than sedation when antihistamines are used as nighttime sleep aids. Because doxylamine may cause marked drowsiness that may be potentiated by other CNS depressants (e.g., sedatives, tranquilizers), the antihistamine should be used in children receiving one of these drugs only under the direction of a physician. As an antihistamine, doxylamine should be used in children 2 to younger than 6 years of age only under the direction of a physician; use of the drug in children younger than 2 years of age is not recommended.

McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 23


Because of the potential for serious adverse reactions to antihistamines in nursing infants, a decision should be made whether to discontinue nursing or doxylamine, taking into account the importance of the drug to the woman.

McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 23


For more Drug Warnings (Complete) data for DOXYLAMINE (11 total), please visit the HSDB record page.


4.3 Minimum/Potential Fatal Human Dose

4. 4= VERY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) 50-500 MG/KG, BETWEEN 1 TEASPOON & 1 OZ FOR 70 KG PERSON (150 LB). /SUCCINATE/

Gosselin, R.E., H.C. Hodge, R.P. Smith, and M.N. Gleason. Clinical Toxicology of Commercial Products. 4th ed. Baltimore: Williams and Wilkins, 1976., p. II-232


4.4 Drug Indication

Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.


5 Pharmacology and Biochemistry
5.1 Pharmacology

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.


5.2 MeSH Pharmacological Classification

Histamine H1 Antagonists

Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)


Antiemetics

Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
DOXYLAMINE
5.3.2 FDA UNII
95QB77JKPL
5.3.3 Pharmacological Classes
Mechanisms of Action [MoA] - Histamine Receptor Antagonists
5.4 ATC Code

R - Respiratory system

R06 - Antihistamines for systemic use

R06A - Antihistamines for systemic use

R06AA - Aminoalkyl ethers

R06AA09 - Doxylamine


5.5 Absorption, Distribution and Excretion

Absorption

Readily absorbed via the gastrointestinal tract.


H1 antagonists are eliminated more rapidly by children than by adults and more slowly in those with severe liver disease. /H1 Receptor Antagonists/

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 590


The H1 antagonists are well absorbed from the gastrointestinal tract. Following oral administration, peak plasma concentrations are achieved in 2 to 3 hours ... . /H1 Receptor Antagonists/

Hardman, J.G., L.E. Limbird, P.B. Molinoff, R.W. Ruddon, A.G. Goodman (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, 1996., p. 588


Elimination and metabolic profiles of the glucuronide products of doxylamine and its N-demethylated metabolites were determined after the oral admin of (14)C-doxylamine succinate (13.3 and 133 mg/kg doses) to male and female Fischer 344 rats. The cumulative urinary and fecal eliminations of these conjugated doxylamine metaboites at the 13.3 mg/kg dose were 44.4 + or - 4.2% and 47.3 + or - 8.1% of the total recoverd dose for male and female rats, respectively. The cumulative urinary and fecal eliminations of conjugated doxylamine metabolites at the 133 mg/kg dose were 55.2 + or - 2.6% and 47.9 + or - 2.5% of the total recovered dose for male and female rats, respectively. The conjugated doxylamine metabolites that were isolated, quantitiated, and identified are doxylamine O-glucuronide, N-desmethyl-doxylamine O-glucuronide, and N,N-didesmethyldoxylamine O-glucuronide.

PMID:1975634 Holder CL et al; J Anal Toxicol 14 (4): 247-51 (1990)


The elimination of doxylamine and metabolites was determined after iv admin of (14)C-doxylamine succinate at 0.7 and 13.3 mg/kg to the adult female rhesus monkey. Although the total recovery of radioactivity was the same for the low- and high-dose studies (90.2%), the rate of plasma elimination of doxylamine and its demethylated metabolite (desmethyldoxylamine) was slower for the high dose group. The 24 hr urinary excretion of doxylamine metabolites, desmethyl- and didesmethyldoxylamine, was significantly incr and the polar doxylamine metabolites were significantly decr as the iv doxylamine succinate dose was incr. The plasma elimination of GC-detected doxylamine was determined after po admin of Bendectin (doxylamine succinate and pyridoxine hydrochloride) /also contains dicyclomine hydrochloride/ at 7, 13.3, and 27 mg/kg to adult female rhesus monkeys. As the dose incr, the clearance of doxylamine decr. A statistically evaluated fit of the po data to a single-compartment, parallel first-order elimination model and a single-compartment, parallel first- and second-order (Michaelis-Menten) elimination model indicated that the more complex model containing the second-order process was most consistent with the observed elimination data. /Doxylamine succinate/

PMID:2520522 Slikker W Jr et al; Reprod Toxicol 3 (3): 187-96 (1989)


5.6 Metabolism/Metabolites

Hepatic.


The conjugated doxylamine metabolites that were isolated, quantitiated, and identified are doxylamine O-glucuronide, N-desmethyl-doxylamine O-glucuronide, and N,N-didesmethyldoxylamine O-glucuronide.

PMID:1975634 Holder CL et al; J Anal Toxicol 14 (4): 247-51 (1990)


Analysis of doxylamine N-oxide and pyrilamine N-oxide as synthetic standards and biologically derived metabolites by thermospray mass spectrometry (TSP/MS) provided (M + H) + ions for each metabolite. ... In addition, TSP/MS and TSP/MS/MS analysis of ring-hydroxylated N-desmethyldoxylamine ... is also reported.

PMID:3382805 Korfmacher WA et al; Biomed Environ Mass Spectrom 15 (9): 501-8 (1988)


5.7 Biological Half-Life

10 hours


The drug has an elimination half-life of about 10 hours in healthy adults.

McEvoy G.K. (ed.). American Hospital Formulary Service-Drug Information 96. Bethesda, MD: American Society of Health-System Pharmacists, Inc. 1996 (Plus Supplements)., p. 22


5.8 Mechanism of Action

Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects.


Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 562-10-7 / Doxylamine API manufacturers, exporters & distributors?

Doxylamine manufacturers, exporters & distributors 1

90

PharmaCompass offers a list of Doxylamine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Doxylamine manufacturer or Doxylamine supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Doxylamine manufacturer or Doxylamine supplier.

PharmaCompass also assists you with knowing the Doxylamine API Price utilized in the formulation of products. Doxylamine API Price is not always fixed or binding as the Doxylamine Price is obtained through a variety of data sources. The Doxylamine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Doxylamine

Synonyms

469-21-6, Dossilamina, Doxylaminum, Doxilminio, (+/-)-doxylamine, 2-dimethylaminoethoxyphenylmethyl-2-picoline

Cas Number

562-10-7

Unique Ingredient Identifier (UNII)

95QB77JKPL

About Doxylamine

Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.

Doxylamine Manufacturers

A Doxylamine manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Doxylamine, including repackagers and relabelers. The FDA regulates Doxylamine manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Doxylamine API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Doxylamine Suppliers

A Doxylamine supplier is an individual or a company that provides Doxylamine active pharmaceutical ingredient (API) or Doxylamine finished formulations upon request. The Doxylamine suppliers may include Doxylamine API manufacturers, exporters, distributors and traders.

click here to find a list of Doxylamine suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Doxylamine USDMF

A Doxylamine DMF (Drug Master File) is a document detailing the whole manufacturing process of Doxylamine active pharmaceutical ingredient (API) in detail. Different forms of Doxylamine DMFs exist exist since differing nations have different regulations, such as Doxylamine USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Doxylamine DMF submitted to regulatory agencies in the US is known as a USDMF. Doxylamine USDMF includes data on Doxylamine's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Doxylamine USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Doxylamine suppliers with USDMF on PharmaCompass.

Doxylamine GMP

Doxylamine Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Doxylamine GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Doxylamine GMP manufacturer or Doxylamine GMP API supplier for your needs.

Doxylamine CoA

A Doxylamine CoA (Certificate of Analysis) is a formal document that attests to Doxylamine's compliance with Doxylamine specifications and serves as a tool for batch-level quality control.

Doxylamine CoA mostly includes findings from lab analyses of a specific batch. For each Doxylamine CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Doxylamine may be tested according to a variety of international standards, such as European Pharmacopoeia (Doxylamine EP), Doxylamine JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Doxylamine USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty